Quanome's all-stock deal values AI antibody startup QAI Labs at $100M
What's the deal? QuanomeDealroom has a profile for this one. Try Dealroom → Technologies (Nasdaq: QNME) has agreed to take a roughly 5% stake in QAI LabsDealroom has a profile for this one. Try Dealroom →, an early-stage life sciences startup building an AI platform for antibody discovery. The all-stock transaction, signed November 4, assigns the stake a $5 million value, implying a QAI valuation of about $100 million.
How it works: QAI Labs will issue 31,579 new shares to Quanome, while Quanome issues 6,541,236 shares of its own stock in return — about 15.97% of its outstanding common stock after the exchange. Closing is subject to customary conditions.
What QAI Labs does: The Sugar Land, Texas company is developing NOVA-3, a platform that uses AI to assemble and rank multi-specific antibody candidates before laboratory work begins. Its quantum-computing algorithms currently run on classical simulators, not quantum hardware.
What's the endgame? The investment advances Quanome's Quantum Life Sciences stream, one of its four strategic pillars. "This investment agreement puts another of Quanome's quantum and AI strategy streams into execution," said chief executive officer Yang Li.
Why now? Pharma interest in AI-designed biologics is building. In early November, AstraZeneca agreed a collaboration with Absci worth up to $247 million for AI-designed antibodies, while UCB partnered with Cradle Therapeutics on antibody discovery.
What could go wrong? QAI Labs remains pre-commercial, and all candidates require laboratory validation, clinical development, and regulatory approval. The deal is also contingent on closing, and the quantum algorithms running on simulators do not establish a practical quantum-computing advantage.
The signal: Investor appetite for AI-assisted drug design is clear, from Antiverse's $9.3 million Series A to Fathom Therapeutics' $55 million round. But Quanome's all-stock structure — swapping equity rather than cash — ties its bet to QAI proving that NOVA-3 can deliver credible results.
Read more: marketscreener.com
Image credit: Generated with Gemini